{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:40:28Z","timestamp":1761237628268},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00347-009-1936-y","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T08:00:26Z","timestamp":1241510426000},"page":"413-419","source":"Crossref","is-referenced-by-count":19,"title":["Antiangiogene Therapie bei Pterygiumrezidiven","Antiangiogenic therapy for pterygium recurrence"],"prefix":"10.1007","volume":"106","author":[{"given":"S.","family":"Leippi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Grehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Geerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,7]]},"reference":[{"key":"1936_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10792-007-9034-0","volume":"27","author":"Akinci","year":"2007","unstructured":"Akinci A, Zilelioglu O (2007) Comparison of limbal-conjunctival autograft and intraoperative 0,02% mitomycin-C for treatment of primary pterygium. Int Ophthalmol 27(5):281\u2013285","journal-title":"Int Ophthalmol"},{"key":"1936_CR2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/ICO.0b013e318165b158","volume":"27","author":"Avisar","year":"2008","unstructured":"Avisar R, Avisar I, Bahar I, Weinberger D (2008) Effect of mitomycin C in pterygium surgery on corneal endothelium. Cornea 27(5):559\u2013561","journal-title":"Cornea"},{"key":"1936_CR3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ajo.2008.08.035","volume":"147","author":"Bahar","year":"2009","unstructured":"Bahar I, Kaiserman I, Lange AP et al (2009) The effect of mitomycin C on corneal endothelium in pterygium surgery. Am J Ophthalmol 147(3):447\u2013452","journal-title":"Am J Ophthalmol"},{"key":"1936_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","volume":"33","author":"Bahar","year":"2008","unstructured":"Bahar I,Kaiserman I, Slomovic A et al (2008) Subcunjunctival Bevacizumab injection for corneal Neovascularisation in recurrent pterygium. Curr Eye Res 33(1):23\u201328","journal-title":"Curr Eye Res"},{"key":"1936_CR5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0886-3350(00)00364-3","volume":"26","author":"Barba","year":"2000","unstructured":"Barba KR, Samy A, Lai C et al (2000) Effect of topical anti-inflammatory drugs on corneal and limbal wound healing. J Cataract Refract Surg 26(6):893\u2013897","journal-title":"J Cataract Refract Surg"},{"key":"1936_CR6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"Bock","year":"2008","unstructured":"Bock F, K\u00f6nig Y, Kruse FE et al (2008) Bevacizumab (Avastin\u00ae) eye drops inhibit corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 246:281\u2013284","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1936_CR7","doi-asserted-by":"crossref","unstructured":"Bock F, Onderka J, Rummelt C et al (2009) Safety profile of topical VEGF-neutraliziation at the cornea. Invest Ophthalmol Vis Sci Jan 17 (Epub ahead of print)","DOI":"10.1167\/iovs.07-1129"},{"key":"1936_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1592\/phco.28.11-supp.23S","volume":"28","author":"Chase","year":"2008","unstructured":"Chase JL (2008) Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28(11 Pt 2):23\u201330","journal-title":"Pharmacotherapy"},{"key":"1936_CR9","first-page":"234","volume":"64","author":"Cern\u00e1k","year":"2008","unstructured":"Cern\u00e1k M, Markovic O, Cern\u00e1k A (2008) The treatment of the rubeosis of the iris and the neovascular glaucoma in proliferative diabetic retinopathy by means of anti-VEGF. Cesk Slov Ophthalmol 64(6):234\u2013236","journal-title":"Cesk Slov Ophthalmol"},{"key":"1936_CR10","first-page":"707","volume":"88","author":"Chang","year":"1989","unstructured":"Chang CT, Chen YL, Lee SH et al (1989) The inhibition of prostaglandin E1-induced corneal neovascularization by steroid eye drops. Taiwan Yi Xui Hui Za Zhi 88(7):707\u2013711","journal-title":"Taiwan Yi Xui Hui Za Zhi"},{"key":"1936_CR11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00055735-199908000-00011","volume":"10","author":"Coroneo","year":"1999","unstructured":"Coroneo MT, Di Girolamo N, Wakefield D (1999) The pathogenesis of Pterygia. Curr Opin Ophthalmol 10(4):282\u2013288","journal-title":"Curr Opin Ophthalmol"},{"key":"1936_CR12","first-page":"29","volume":"52","author":"Cr\u0103i\u0163oiu","year":"2008","unstructured":"Cr\u0103i\u0163oiu S, Ciprian L, Rodica M et al (2008) Etiopathogenic aspects in development and evolution of pterigyum. Oftalmologia 52(2):29\u201334","journal-title":"Oftalmologia"},{"key":"1936_CR13","doi-asserted-by":"crossref","unstructured":"Cursiefen C, Bock F, Horn FK et al (2009) GS-101 antisence oligonucleotide eye drops inhibit corneal neovascularization: Interim results of a randomized phase II trial. Ophthalmology (in press)","DOI":"10.1016\/j.ophtha.2009.04.016"},{"key":"1936_CR14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/ICO.0b013e318180e4fb","volume":"27","author":"Diaz","year":"2008","unstructured":"Diaz L, Villegas VM, Emanuelli A, Izquierdo NJ (2008) Efficacy and safety of intraoperative mitomycin C as adjunct therapy for pterygium surgery. Cornea 27(10):1119\u20131121","journal-title":"Cornea"},{"key":"1936_CR15","doi-asserted-by":"crossref","unstructured":"Donald T, Tan H, Edward J (2002) Ocular Surface Disease Medical and Surgical Management, Springer Verlag, Kapitel 6 Pterygium 65\u201391","DOI":"10.1007\/0-387-21570-0_6"},{"key":"1936_CR16","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1167\/iovs.05-1130","volume":"47","author":"DiGirolamo","year":"2006","unstructured":"DiGirolamo et al (2006) UVB-Mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signalling. Invest Ophhalmol Vis Sci 47(6):2430\u20132437","journal-title":"Invest Ophhalmol Vis Sci"},{"key":"1936_CR17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.eye.6701728","volume":"19","author":"Fernandes","year":"2005","unstructured":"Fernandes M, Sangwan VS, Bansal AK et al (2005) Outcome of pterygium surgery: Analysis over 14 years. Eye 19(11):1182\u20131190","journal-title":"Eye"},{"key":"1936_CR18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","volume":"82","author":"Gan","year":"2004","unstructured":"Gan L, Fagerholm P, Palmblad J (2004) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82(5):557\u2013563","journal-title":"Acta Ophthalmol Scand"},{"key":"1936_CR19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2005.01.023","volume":"112","author":"Gebhard","year":"2005","unstructured":"Gebhard M, Mentlein R, Geerling G, Paulsen FP (2005) Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112(6):1023\u20131030","journal-title":"Ophthalmology"},{"key":"1936_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00464475","volume":"379","author":"Lemercier","year":"1978","unstructured":"Lemercier G, Cornand G, Burckhart MF (1978) A Pinguecula et pterygion: Etude histopathologique et ultrastructurale Path. Virchows Arch Anat Histol 379(4):321\u2013333","journal-title":"Virchows Arch Anat Histol"},{"key":"1936_CR21","first-page":"224","volume":"93","author":"Hille","year":"1996","unstructured":"Hille K, H\u00f6h K, Gross A, Ruprecht KW (1996) Prospective study of surgical therapy of pterygium: Bare sclera technique vs. free conjunctiva-limbus transplant. Ophthalmology 93(3):224\u2013226","journal-title":"Ophthalmology"},{"key":"1936_CR22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00006324-198604000-00006","volume":"63","author":"Hoban","year":"1986","unstructured":"Hoban BP, Collin HB (1986) Effects of salicylate and steroid on neutrophil migration and corneal blood vessel growth. Am J Optom Physiol Opt 63(4):271\u2013276","journal-title":"Am J Optom Physiol Opt"},{"key":"1936_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/bmj.309.6946.43","volume":"309","author":"Butche","year":"1994","unstructured":"Butche J Mr, Austin M, McGalliard J, Bourke RD (1994) Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ 309(6946):43","journal-title":"BMJ"},{"key":"1936_CR24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0161-6420(92)31850-0","volume":"99","author":"Mackenzie","year":"1992","unstructured":"Mackenzie FD, Hirst LW, Battistutta D, Green A (1992) Risk analysis in the development of pterygia. Ophthalmology 99(7):1056\u20131061","journal-title":"Ophthalmology"},{"key":"1936_CR25","doi-asserted-by":"crossref","unstructured":"Moraczewski AL, Lee RK, Palmberg PF et al (2008) Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol (Epub)","DOI":"10.1136\/bjo.2008.151472"},{"key":"1936_CR26","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","volume":"113","author":"Moshfeghi","year":"2006","unstructured":"Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113(11):2002, 1\u201312","journal-title":"Ophthalmology"},{"key":"1936_CR27","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0161-6420(97)30197-3","volume":"104","author":"Prabhasawat","year":"1997","unstructured":"Prabhasawat et al (1997) Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 104(6):974\u2013985","journal-title":"Ophthalmology"},{"key":"1936_CR28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","volume":"27","author":"Priyanka","year":"2008","unstructured":"Priyanka P. Doctor, MD, (Ophth.), Bhat PV, MD, Foster CS, MD (2008) Subkonjunctival Bevacizumab for Corneal Neovascularization. Cornea 27(9):992\u2013995","journal-title":"Cornea"},{"key":"1936_CR29","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"112","author":"Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112(6):1048\u20131053","journal-title":"Ophthalmology"},{"key":"1936_CR30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Laser Imaging 36(4):331\u2013335","journal-title":"Ophthalmic Surg Laser Imaging"},{"key":"1936_CR31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.82.6.661","volume":"82","author":"S\u00e1nchez-Thorin","year":"1998","unstructured":"S\u00e1nchez-Thorin JC, Rocha G, Yelin JB (1998) Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol 82(6):661\u2013665","journal-title":"Br J Ophthalmol"},{"key":"1936_CR32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173\u2013180","journal-title":"J Surg Oncol"},{"key":"1936_CR33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1442-9071.1991.tb00661.x","volume":"19","author":"Sebban","year":"1991","unstructured":"Sebban A, Hirst LW (1991) Pterygium reccurence rate at the Princess Alexandra Hospital. Aust NZ J Ophthalmol 19(3):203\u2013206","journal-title":"Aust NZ J Ophthalmol"},{"key":"1936_CR34","unstructured":"Theobald S (1887) The Pathogenesis of Pterygium. Trans Am Ophthalmol Soc 537\u2013541"},{"key":"1936_CR35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0004-27492006000100012","volume":"69","author":"Viveiros","year":"2006","unstructured":"Viveiros MM, Schellini SA, Rogato S et al (2006) Fibroblasts from primary and recurrent pterygia and Tenon\u2019s capsule in cell culture. Arq Bras Oftalmol 69(1):57\u201362","journal-title":"Arq Bras Oftalmol"},{"key":"1936_CR36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.2008.145797","volume":"93","author":"Wu","year":"2009","unstructured":"Wu PC, Chen YJ (2009) Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Br Ophthalmol 93(2):150\u2013154","journal-title":"Br Ophthalmol"},{"key":"1936_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","volume":"28","author":"Wu","year":"2009","unstructured":"Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical Bevacizumab eyedrops for limbal-conjunctival neovascularisation in impending recurrent pterygium. Cornea 28(1):103\u2013104","journal-title":"Cornea"},{"key":"1936_CR38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00347-006-1354-3","volume":"103","author":"Ziemssen","year":"2006","unstructured":"Ziemssen F, Bartz-Schmidt KU, Grisanti S (2006) (Neben-) Wirkungen der VEGF-Inhibition. Ophthalmologe 103(6):484\u2013492","journal-title":"Ophthalmologe"},{"key":"1936_CR39","doi-asserted-by":"crossref","unstructured":"Bachmann BO, Bock F, Wiegand SJ et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126(1)71\u201377","DOI":"10.1001\/archopht.126.1.71"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-009-1936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-009-1936-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-009-1936-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:02:26Z","timestamp":1684976546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-009-1936-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1007\/s00347-009-1936-y","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}